Welcome to SYNIMMUNE

SYNIMMUNE GmbH is a biotechnology company focusing on the development of novel mono- and bispecific antibodies for improved immunotherapy of hematopoietic and solid malignancies.


The company was founded in 2010 as a spin-off of the Department of Immunology at the University of Tübingen, which is headed by Prof. Dr. Hans-Georg Rammensee.


Our goal is to enhance the therapeutic efficacy of antibody treatment by improving the selective activation of immune effector cells, and to bridge the “translational gap” between conception and clinical evaluation as fast as possible.
To this end, SYNIMMUNE GmbH is establishing its own GMP-compliant production unit and works in close co-operation with the University Hospital in Tübingen, Germany.

Read more

 

 

News

SYNIMMUNE congratulates Hans-Georg Rammensee for receiving the Ernst Jung Prize for Medicine 2016.

Please refer to the press release by the Ernst Jung Stiftung for further informations.